多中心、双盲、随机、安慰剂对照NefIgArd试验A部分结果:评估靶向释放布地奈德治疗原发性免疫球蛋白A肾病的疗效
NefIgArd是一项多中心、随机、双盲、安慰剂对照的两部分3期试验。A部分纳入199例原发性IgA肾病患者,接受Nefecon(16 mg/d)或安慰剂治疗9个月并再观察3个月。主要终点为9个月时24小时尿蛋白肌酐比(UPCR):Nefecon组较安慰剂组降低27%,eGFR差异为3.87 ml/min/1.73 m²,均具统计学显著性。
要点
- Nefecon 16 mg/d治疗9个月,UPCR较安慰剂降低27%。
- 9个月时eGFR较安慰剂组差异为3.87 ml/min/1.73 m²。
- Nefecon耐受性良好,治疗中出现的不良事件多为轻至中度且可逆。
核心结论
- NefIgArd是首个显示UPCR和eGFR具有临床重要改善的3期IgA肾病试验,并证实了2b期NEFIGAN研究的结果。
研究设计与样本
- NefIgArd为多中心、随机、双盲、安慰剂对照的两部分3期试验(ClinicalTrials.gov: NCT03643965)。
- A部分纳入199例原发性IgA肾病且有进展至肾衰竭风险的患者,接受Nefecon(16 mg/d)或安慰剂治疗9个月,并再观察3个月。
主要发现
- 9个月时,Nefecon组24小时UPCR较安慰剂组降低27%。
- 9个月时,Nefecon组eGFR较安慰剂组差异为3.87 ml/min/1.73 m²,均具统计学显著性。
- Nefecon耐受性良好,治疗中出现的不良事件大多为轻至中度且可逆。
- B部分正在进行中,后续将另行报告。
关键数值与推荐
- A部分主要终点为治疗9个月时的24小时UPCR。
- 次要疗效终点包括9个月和12个月时的eGFR以及12个月时的UPCR。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase 2b NEFIGAN trial. To verify these findings, the phase 3 NefigArd trial tested the efficacy and safety of nine months of treatment with Nefecon (16 mg/d) versus placebo in adult patients with primary IgAN at risk of progressing to kidney failure (ClinicalTrials.gov: NCT03643965). NefIgArd was a multicenter, randomized, double-blind, placebo-controlled two-part trial. In Part A, 199 patients with IgAN were treated with Nefecon or placebo for nine months and observed for an additional three months. The primary endpoint for Part A was 24-hour urine protein-to-creatinine ratio (UPCR) after nine months. Secondary efficacy outcomes evaluated included estimated glomerular filtration rate (eGFR) at nine and 12 months and the UPCR at 12 months. At nine months, UPCR was 27% lower in the Nefecon group compared with placebo, along with a benefit in eGFR preservation corresponding to a 3.87 ml/min/1.73 m2 difference versus placebo (both significant). Nefecon was well-tolerated, and treatment-emergent adverse events were mostly mild to moderate in severity and reversible. Part B is ongoing and will be reported on later. Thus, NefIgArd is the first phase 3 IgA nephropathy trial to show clinically important improvements in UPCR and eGFR and confirms the findings from the phase 2b NEFIGAN study.
引用
- Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2022. PMID: 36270561. doi:10.1016/j.kint.2022.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。